| Literature DB >> 32299476 |
Chiara Mameli1, Giulia Zichichi2, Nasim Mahmood3, Siham Chafai Elalaoui4, Adnan Mirza5, Poonam Dharmaraj6, Marco Burrone2, Elisa Cattaneo7, Jayesh Sheth8, Ajit Gandhi8, Gurpreet Singh Kochar9, Fowzan Sami Alkuraya10, Madhulika Kabra11, Giuseppe Mercurio2, Gianvincenzo Zuccotti12.
Abstract
BACKGROUND: Raine syndrome (RS) is a rare autosomal recessive disorder caused by biallelic loss-of-function mutations of FAM20C. The most common clinical features are microcephaly, exophthalmos, hypoplastic nose and severe midface hypoplasia, leading to choanal atresia. The radiological findings include generalized osteosclerosis and brain calcifications. RS is usually lethal during the neonatal period due to severe respiratory distress. However, there exists a non-lethal RS form, the phenotype of which is extremely heterogeneous. There is paucity of data about clinical course and life expectancy of these patients.Entities:
Keywords: Children; Osteosclerosis; Raine syndrome; Rickets
Mesh:
Substances:
Year: 2020 PMID: 32299476 PMCID: PMC7164176 DOI: 10.1186/s13023-020-01373-0
Source DB: PubMed Journal: Orphanet J Rare Dis ISSN: 1750-1172 Impact factor: 4.123
Fig. 11a-b: Case I at the age of 14 years. 1c: case II at 3 days of life. 1d: case II at 12 months of life. 1e: case III. 1f: case IV at 6 years of age. 1g: Case V (with permission from reference n° 17)1H: case V (with permission from reference n° 17)
Summary of antenatal and postnatal features in non-lethal RS individuals
| Pedigree number | Case I | Case II | Case III | Case IV | Case V | Case VI | Case VII |
|---|---|---|---|---|---|---|---|
| Unpublished | Unpublished | Unpublished | [ | [ | [ | [ | |
| F | M | M | F | M | F | M | |
| Pakistani | Pakistani | Pakistani | Indian | Pakistani | Moroccan | Moroccan | |
| No | One | No, two previous spontaneous abortions | No | No | Noa | Noa | |
| NA | 37 | 37 | 36 | 36 | 40 | 39 | |
| NA | 2900/30° | 3500/90° | 2750/60° | 2200/10° | 3500/60° | 3750/80° | |
| NA | 50/50° | 47/3° | NA | NA | NA | NA | |
| NA | Choanal stenosis-respiratory distress | Bilateral choanal atresia-respiratory distress | Normal | Choanal atresia-respiratory distress - Hypocalcemic seizures | Normal | Neonatal cerebral hypoxia-ischemia | |
c.le percentile; F female, M male NA not available; wks weeks; aOne child deceased at 7 months (the diagnosis was not made)
Summary of clinical and radiologic features at diagnosis in non-lethal RS individuals
| Pedigree number | Case I* | Case II* | Case III | Case IV | Case V | Case VI° | Case VII° |
|---|---|---|---|---|---|---|---|
| 12 yrs | 5 mo | 4 mo | 6 yrs | 2 mo | 17 yrs | 14 yrs | |
| Developmental delay/Seizures | +/− | +/− | +/− | +/+ | −/+ | +/+ | +/− |
| Hearing/vision impairment | +/+ | −/− | −/− | – | −/− | +/− | +/− |
| Midface hypoplasia/ Microcephaly | −/+ | +/ + | +/+ | +/+ | +/+ | +/− | +/+ |
| Depressed nasal bridge/ Hypoplastic nose | −/− | +/+ | +/+ | +/+ | +/− | +/+ | +/+ |
| Exophthalmos | – | + | + | – | + | + | + |
| Low set ears | – | – | + | + | + | + | + |
| Hypertelorism | + | – | + | + | + | + | + |
| Gingival hypertrophy | – | – | + | – | – | + | + |
| Dental malformations | + | – | + | – | – | + | + |
| Limb malformations | + | – | – | + | – | + | + |
| Bowing of long bones | – | – | – | – | + | – | – |
| Signs of rickets | – | – | – | – | + | – | – |
| Cerebral calcifications | + | + | – | – | + | + | – |
| Osteosclerosis of skull | – | + | + | + | + | – | – |
| Osteosclerosis of long bones | - | + | + | + | + | – | – |
| Short stature | |||||||
| Hypophosphatemia | |||||||
| Hypocalcemia | |||||||
| Rickets | |||||||
| 25 OH Vitamin D deficiency | |||||||
mo months; yrs years +: present; −: absent; */° siblings
Genotype
| Pedigree number and reference | Case I | Case II | Case III | Case IV [ | Case V [ | Case V I[ | Case VII [ |
|---|---|---|---|---|---|---|---|
| c.1351G > A (p.Asp451Asn) | c.1351G > A (p.Asp451Asn) | c.496G > T (p.E166X) | c1630C > T (p.Arg544Trp) | c.1135G > A (p.G379R) | c.676 T > A (p.Trp226Arg) | c.676 T > A. (p.Trp226Arg) | |
| Exon 7 | Exon 7 | Exon 1 | Exon 10 | Exon 6 | Exon 2 | Exon 2 | |
| Homozygous | Homozygous | Homozygous | Homozygous | Homozygous | Homozygous | Homozygous | |
| Pathogenic based on LOVD database | Pathogenic based on LOVD database | Pathogenic based on PVS1 PM2 PP4 | Pathogenic according to ACMG guidelines | Pathogenic according to ACMG guidelines | Pathogenic based on: SIFT (score0) Polyphen-2 (score 0.993) Mutation Taster (score 0.999) | Pathogenic based on: SIFT (score0) Polyphen-2 (score 0.993) Mutation Taster (score 0.999) | |
| Sanger | NGS | NGS | NGS and Sanger | Sanger | NGS | Sanger |
ACMG American College of Medical Genetics and Genomics; LOVD Leiden Open Variation Database; NGS next generation sequencing
Biochemical features at diagnosis
| Case I | Case II | Case III | Case IV | Case V | Case VI | Case VII | |
|---|---|---|---|---|---|---|---|
10.1 mg/dl (nv 8.8–10.8) | 6.4 mg/dl (nv 8.8–10.8) | 1.78 mmol/l (nv 2.20–2.79) | 10 mg/dl (nv 8–11 mg/dl) | 1.92 mmol/L (nv 2.20–2.79) | 2.45 mmol/l (nv 2.2–2.6) | NA | |
2.7 mg/dl (nv 4–7) | 3.9 mg/dl (nv 4–7) | 1.33 mmol/l (nv 1.36–2.26) | NA | 0.75 mmol/L (nv 1.36–2.26) | 2.2 mg/dl (nv 2.5–4.5) | NA | |
547 U/L (nv 140–400 | 454 U/L (nv 140–400 | 743 IU/L (nv 187–1197) | NA | 5605 IU/L (nv 187–1197) | 70 IU/L (nv 40–100) | NA | |
51.3 pg/ml (nv 15–65) | 129 pg/ml (nv 15–65) | NA | NA | 72 pmol/L (nv 1.1–6.9) | 95.3 pg/ml (nv 15–68) | NA | |
45.6 ng/ml (nv > 30) | 13.8 ng/ml (nv > 30) | NA | NA | < 40 nmol/L (nv > 50 nmol/L) | NA | NA | |
| NA | NA | NA | NA | 72 | NA | NA | |
| NA | NA | NA | NA | 157 RU/ml (nv 0–100) | NA | NA |
ALP alkaline phosphatase; FGF23 fibroblast growth factor 23; NA not available; NV normal value; PTH parathormone; TRP tubular reabsorption of phosphate; ys years; 25OHD 25-Hydroxy Vitamin D.
Biochemical features during follow-up
| Case I | Case II | Case V | |||||
|---|---|---|---|---|---|---|---|
| 12 ys 6 mo | 13 ys 7 mo | 14 ys | 4 mo | 1 y 9 mo | 2 mo | 7 ys and 3 mo | |
9.6 mg/dl (nv 8.8–10.8) | 9.8 mg/dl (nv 8.8–10.8) | 9.7 mg/dl (nv 8.8–10.8) | 10 mg/dl (nv 8.8–10.8) | 10.1 mg/dl (nv 8.8–10.8) | 1.92 mmol/L (nv 2.20–2.79) | 2.51 mmol/L (nv 2.20–2.79) | |
2.6 mg/dl (nv 4–7) | 2.2 mg/dl (nv 4–7) | 2.6 mg/dl (nv 4–7) | 2.2 mg/dl (nv 4–7) | 2.1 mg/dl (nv 4–7) | 0.75 mmol/L (nv 1.36–2.26) | 0.73 mmol/L (nv 1.36–2.26) | |
555 U/L (nv 140–400) | 611 U/L (nv 140–400) | 419 U/L (nv 140–400) | 805 U/L (nv 140–400) | 487 U/L (nv 140–400) | 5605 IU/L (nv 187–1197) | 3874 IU/L (nv 187–1197) | |
79 pg/ml (nv 15–65) | 104 g/ml (nv 15–65) | 74 pg/ml (nv 15–65) | 71 pg/ml (nv 15–65) | 64 pg/ml (nv 15–65) | 72 pmol/L (nv 1.1–6.9) | 24 pmol/L (nv 1.1–6.9) | |
39.2 ng/ml (nv > 30) | 35.2 ng/ml (nv > 30) | 39.2 ng/ml (nv > 30) | 57.9 ng/ml (nv > 30) | 51.2 ng/ml (nv > 30) | < 40 nmol/L (nv > 50 nmol/L) | 17 nmol/L (nv > 50 nmol/L) | |
| NA | 66 | NA | 76 | 73 | 72 | NA | |
| NA | NA | NA | NA | NA | 157 RU/ml (nv 0–100) | NA | |
(< 3 ys:; nv < 0.5 > 3 ys: nv < 0.39) | 0.22 | 0.09 | 0.12 | 0.026 | 0.10 | Normal | Normal |
| – | yes | no | – | yes | – | yes | |
| – | no | no | – | yes | – | yes | |
| – | yes | yes | yes | yes | – | yes | |
ALP alkaline phosphatase; CaU/CrU urine calcium to creatinine ratio; FGF23 fibroblast growth factor 23; Mo months; NA not available; NV normal value; PTH parathormone; TRP tubular reabsorption of phosphate; 25OHD 25-Hydroxy Vitamin D; ys years; alast measurements before stopping the therapy with phosphate salts